Clinical trial · no report yet · Phase 2
TRUDI
TRUDI: TDXD+Durva in HER2+/Low IBC
- NCT05795101 ↗
- Recruiting
- Filipa Lynce, MD
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 9 | |
| YouTube | 2 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Invasive Breast Cancer; Inflammatory Breast Cancer Stage III; HER2-positive Breast Cancer; HER2 Low Breast Adenocarcinoma; Breast Cancer
- Interventions
- Trastuzumab deruxtecan; Durvalumab
- Arms
- HER2 Positive · Experimental
- HER2-Low · Experimental
- Enrollment
- 63 (estimated)
- Primary outcomes
- Pathological complete response (pCR) Rate
- Sponsor
- Filipa Lynce, MD with AstraZeneca, Daiichi Sankyo
- Start
- May 4, 2023
- Primary completion
- Dec 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05795101 · updated Oct 9, 2026